Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IRWD · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis… NCT05740007 · Interstitial Cystitis, Bladder Pain Syndrome IW-3300 rectal foam, Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 2 | Terminated | 98 | Jan 23, 2025 | Registry ↗ |
| Feb 2, 2024 | A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects NCT05362695 · Healthy Volunteers IW-3300, Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 1 | Completed | 18 | Jun 30, 2022 | Registry ↗ |
| Dec 8, 2023 | A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers NCT05188261 · Healthy Volunteers IW-3300, Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 1 | Completed | 32 | Mar 9, 2022 | Registry ↗ |
| Aug 11, 2022 | Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction NCT01107236 · Healthy IW-6118, Matching Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | 90 | Aug 2010 | Registry ↗ |
| Dec 6, 2021 | A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndro… NCT02837783 · Irritable Bowel Syndrome Characterized by Constipation Linaclotide, Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 4 | Terminated | 20 | Oct 31, 2018 | Registry ↗ |
| Nov 4, 2021 | A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Rena… NCT03226899 · Gout, Chronic Kidney Disease (CKD) Lesinurad, XOI | IRWD Ironwood Pharmaceuticals, Inc. | Phase 4 | Terminated | 242 | Feb 25, 2019 | Registry ↗ |
| Aug 19, 2021 | A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) R… NCT03561090 · Gastroesophageal Reflux Disease (GERD) IW-3718, placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 3 | Terminated | 495 | Oct 7, 2020 | Registry ↗ |
| Aug 18, 2021 | Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Rec… NCT03561883 · Gastroesophageal Reflux Disease (GERD) IW-3718, placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | 609 | Jul 28, 2020 | Registry ↗ |
| Mar 12, 2021 | A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Sy… NCT03931785 · Irritable Bowel Syndrome With Diarrhea (IBS-D) MD-7246, Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | 515 | Feb 26, 2020 | Registry ↗ |
| Dec 1, 2020 | A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) NCT03573908 · Irritable Bowel Syndrome Characterized by Constipation Linaclotide, Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | 614 | Mar 13, 2019 | Registry ↗ |
| Apr 24, 2020 | Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) NCT02559206 · Irritable Bowel Syndrome With Constipation Linaclotide, Matching Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | 759 | Sep 30, 2016 | Registry ↗ |
| Oct 15, 2019 | A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) NCT02637557 · Gastroesophageal Reflux Disease IW-3718, Matching Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | 282 | Apr 26, 2017 | Registry ↗ |
| Jul 29, 2019 | Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxin… NCT03856970 · Healthy Volunteers Microgestin®, Levothyroxine | IRWD Ironwood Pharmaceuticals, Inc. | Phase 1 | Completed | 87 | Jun 25, 2019 | Registry ↗ |
| Feb 19, 2018 | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irrit… NCT00730171 · Irritable Bowel Syndrome With Constipation, Chronic Constip… Linaclotide | IRWD Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | 1,743 | Mar 2012 | Registry ↗ |
| Jun 15, 2017 | Trial of Linaclotide in Patients With Chronic Idiopathic Constipation NCT02291679 · Chronic Idiopathic Constipation Linaclotide, Matching Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 3 | Completed | 1,223 | Aug 2015 | Registry ↗ |
| Dec 5, 2016 | Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) NCT02289846 · Diabetic Gastroparesis IW-9179, Matching Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | 90 | Dec 2015 | Registry ↗ |
| Aug 1, 2016 | Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive t… NCT02030925 · Gastroesophageal Reflux IW-3718, Matching Placebo | IRWD Ironwood Pharmaceuticals, Inc. | Phase 2 | Completed | 93 | Dec 2014 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:27 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances